Archives
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br Breast cancer The interactions between LOX and COX enzyme
2024-05-21

Breast cancer The interactions between 15-LOX and COX enzymes also affect the outcome of breast cancer. Indomethacin, a COX-1 and COX-2 inhibitor, decreased the growth of human breast cancer (BC) cells in nude mice, as well as slowed the rate of lung metastasis formation [41]. The levels of 12-HE
-
Analysis of ASK crystal structures as well as an
2024-05-21

Analysis of ASK1 crystal structures as well as an investigation of how Fmoc-D-Lys(Boc)-OH 4 might bind were undertaken to understand opportunities for engaging Gln756. To this end a docking model derived from PDB 3VW622 was used to predict the binding mode of amide 4 in the ASK1 active site as show
-
Assessment of antibiotic appropriateness is receiving increa
2024-05-21

Assessment of antibiotic appropriateness is receiving increased attention in the face of growing concerns about the emergence of MDROs, as well as the rise in adverse outcomes associated with antibiotic use such as C. difficile infection. In this study, 15% of cultured Gram-negative organisms met th
-
Sorafenib was the first small RTK inhibitor drug
2024-05-21

Sorafenib was the first small RTK inhibitor drug to be developed and was initially approved against renal cell carcinoma, then against hepatocellular carcinoma (HCC) and more recently for differentiated thyroid treatment [111]. Sunitinib soon followed, being approved for gastrointestinal stromal tum
-
Our surprising results show that
2024-05-21

Our surprising results show that AAD-treated tumors adjacent to adipose tissues and in steatotic liver continue to grow in the presence of a minimal number of microvessels. In non-adipose tumor models, the similar degree of vascular suppression is translated into marked suppression of tumor growth.
-
Recent work has detailed the impact of genetic deletion of
2024-05-21

Recent work has detailed the impact of genetic CHS828 of AMPK in the liver, revealing only minor phenotypes upon removal in mice (Boudaba et al., 2018). However, these studies very elegantly showed the potential for small molecule-mediated activation of AMPK to elicit large changes in lipid metabol
-
Pathogen infected macrophages release exosomes
2024-05-21

Pathogen-infected A 779 release exosomes associating with pathogen-associated molecular patterns (PAMPs) such as LPS and lipoprotein derived from microorganisms [29,30]. Exosomes released by bacterially infected, but not uninfected, macrophages stimulate macrophages to release inflammatory mediators
-
br AKT signaling is essential
2024-05-21

AKT signaling is essential during early dorsal patterning, neural crest induction and maturation AKT signaling modulates EMT and migration of the neural crest cells The defining feature of NC cells is their delamination from the dorsal neural epithelium. At the end of neurulation, mature premi
-
The functional observations from the present study are based
2024-05-21

The functional observations from the present study are based on neoplastic 2-Deoxycytidine synthesis (HSY), and comparative expressions between normal salivary and pleomorphic adenoma tissues. However, there is a paucity of information on AhR expression and function in normal salivary gland, not ne
-
Introduction hydroxytryptamine HT is found throughout the bo
2024-05-20

Introduction 5-hydroxytryptamine (5-HT) is found throughout the body and influences smooth muscle activity in various tissues including the intestine, vasculature and urinary Gliotoxin (Kim and Camilleri, 2000, Klarskov and Horby-Petersen, 1986, Mohammad-Zadeh et al., 2008). The current classifica
-
This raises an important question May the lack
2024-05-20

This raises an important question: May the lack of ethnolinguistic theories and of explicit references to language be related to the lack of contact with other groups and their languages? For the past few centuries at least, the Aché seem to have been culturally and linguistically isolated (Hill and
-
A previous study reported that the serotonergic mechanism wa
2024-05-20

A previous study reported that the serotonergic mechanism was involved in the psychological stress-induced alteration in synaptic plasticity in the rat hippocampal CA1 field (Matsumoto et al., 2004). Sumitaka Inoue et al. (Inoue et al., 2014) reported that pretreatment with a 5-HT1A receptor partial
-
For both the hydroxylation and lyase reactions the heme
2024-05-20

For both, the 17α-hydroxylation and 17, 20-lyase reactions, the heme iron center of P450 17A1 receives electron reducing equivalents from CPR. Both reactions require one pair of electrons and molecular oxygen for the conversion of the substrate into product in each catalytic cycle. However, the 17,2
-
HCC aetiology is multifactorial and the disease is
2024-05-20

HCC aetiology is multifactorial and the disease is often preceded by other conditions including liver fibrosis and cirrhosis that are associated with HCV, HBV, alcoholic and non-alcoholic hepatitis. The discovery of new therapeutic targets will require a greater understanding of the pathogenic mecha
-
Aurora A or B selective and pan aurora inhibitors
2024-05-20

Aurora -A or -B selective and pan-aurora inhibitors have demonstrated different preclinical and clinical therapeutic efficacies [2,[19], [20], [21], [22], [23]]. For example, clinical trials for a pan-Aurora inhibitor VX-680 (developed by Vertex) were halted at phase II for toxicity reasons (one cas
16300 records 153/1087 page Previous Next First page 上5页 151152153154155 下5页 Last page